amgen see mix neulasta biosimilar pressur
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim oct
price data oct
rate updat oct
currenc amount express
methodolog valu compani
saw declin third-quart revenu due
gener biosimilar version
hyperparathyroid drug sensipar white
blood cell booster neulasta demand
growth newer product like osteoporosi drug prolia
sale cholesterol-low therapi repatha
remain double-digit territori uptak
biosimilar portfolio line bullish
saw declin encourag
abil manufactur improv larg off-set
pressur biosimilar midpoint higher
guidanc put firm high end prior
guidanc consist exist forecast
perform give us confid stabil
cash flow wide moat expect
signific chang fair valu estim rais
fair valu estim per share septemb
incorpor otezla acquisit good fit
enbrel amgevita
franchis otezla remain solid perform
throughout forecast particularli carv
nich mild moder psoriasi segment
current phase
focus key franchis repatha
sale growth encourag demand growth
even higher firm still face headwind price
reduct annual late year although sale
growth meet high expect continu
monitor potenti new competit threat space
still sensit point launch repatha
even medicin inclisiran reach market
schedul conveni twice year
administr profil versu month repatha
think physician wait cardiovascular outcom
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
leader biotechnology-bas human therapeut
histor expertis renal diseas cancer supportive-car product
flagship drug includ red blood cell booster epogen aranesp immun
system booster neulasta enbrel inflammatori
diseas introduc first cancer therapeut vectibix
receiv approv bone-strengthen drug prolia/xgeva
acquisit onyx bolster firm therapeut oncolog
portfolio nexavar kyproli recent launch includ repatha
cholesterol-low aimovig migrain
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
data like prescrib inclisiran
anticip stem mix price
volum pressur howev sale prolia driven
demand immunolog drug enbrel driven price
higher expect sale new osteoporosi
drug even also higher expect
million quarter drug see launch europ
pipelin respiratori drug tezepelumab part
collabor astrazeneca phase data
asthma late recent enter phase copd
well phase ad also continu phase data
encourag could make competit regeneron
sanofi dupix launch asthma
oncolog kra inhibitor separ
phase studi lung colorect cancer
expect see addit data next year oct
mirati partner novarti report solid earli data
kra inhibitor think look
similar data sever
merck vaccin
phase also alreadi test combin
keytruda could broader efficaci kra
earlier-stag develop
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
